Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
heart failure
Pharma
Unapproved in US for decades, levosimendan stumbles in ph. 3
Despite the flop, Tenax has zeroed in on a prespecified subgroup of patients with greater disease burden and plans to request a meeting with the FDA.
Angus Liu
Aug 10, 2026 4:40pm
Fierce Biotech
Cytokinetics doesn't want Big Pharma help to overtake Camzyos
Nov 18, 2025 1:30pm
Merck set to advance Winrevair to phase 3 in new indication
Nov 18, 2025 11:22am
Merck, Bayer's Verquvo posts perplexing trial fail
Sep 2, 2025 11:06am
FDA broadens label for Bayer's Kerendia to treat heart failure
Jul 14, 2025 8:39am
Novartis asks court for swift decision in Entresto patent case
Jun 6, 2025 10:26am
